Abstract
As long as it is impossible to prevent or to correct the altered expression of genetic information in malignant cells, tumor chemotherapy has to aim at the elimination of malignant cells by means of cytostatic or cytocidal drugs that are as selective as possible for a given tumor. The minimal difference in the sensitivity of normal and neoplastic cells remains a critical limitation in the use of effective agents, many of which are antimetabolites that inhibit enzymes of essential metabolic pathways on the basis of a structural similarity with physiological intermediates, interfering thereby with cellular growth and proliferation. This may be illustrated by the blockade of thymidylate synthetase induced by 5-fluoro-5′-deoxyuridinemonophosphate (FdUMP), a metabolite of the pyrimidine analog 5-fluorouracil (reviewed by Heidelberger [5]. The consequent depletion of deoxythymidine-5′-monophosphate (dTMP) and deoxythymidine-5′-triphosphate (dTTP) pools should result in DNA synthesis inhibition due to substrate deficiency. This is one of several mechanisms by which fluorinated pyrimidines preferentially inhibit proliferating cells. This effect may be circumvented, however, by dTMP formation from deoxythymidine on the salvage pathway, and this underlines the critical importance of quantitative metaboliteantimetabolite relationships in tumor chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anderson EP, Brockman RW (1964) Feedback inhibition of uridine kinase by cytidine triphosphate and uridine triphosphate. Biochim Biophys Acta 91: 380–386
Anukarahanonta T, Holstege A, Keppler D (1980) Selective enhancement of 5-fluorouridine uptake and action in rat hepatomas in vivo following pretreatment with D-galactosamine and 6-azauridine or N-(phosphonoacetyl)-L-aspartate. Eur J Cancer 16: 1171–1180
Bennett LL Jr, Smithers D, Rose LM, Adamson DJ, Thomas HJ (1979) Inhibition of synthesis of pyrimidine nucleotides by 2-hydroxy-3-(3,3-dichloroallyl)-1,4-naphthoquinone. Cancer Res 39: 4868–4874
Decker K, Keppler D (1974) Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev Physiol Biochem Pharmacol 71: 77–106
Heidelberger C (1975) Fluorinated pyrimidines and their nucleosides. In: Sartorelli AC, Johns DC (eds) Antineoplastic and immunosuppressive agents, part II. Springer, Berlin Heidelberg New York, pp 193–231
Holstege A, Herrmann B, Keppler D (1978) Increased formation of nucleotide derivatives of 5-fluorouridine in hepatoma cells treated with inhibitors of pyrimidine synthesis and D-galactosamine. FEBS Lett 95: 361–365
Holstege A, Herrmann B, Anukarahanonta T, Pausch J, Keppler D (1979) Die Wirkung von 5-Fluoruridin in Kombination mit Antipyrimidinen in Tumorzellen. Verh Deutsch Ges Inn Med 85: 1296–1300
Jones ME (1980) Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis. Ann Rev Biochem 49: 253–279
Keppler D (1975) Consequences of uridine triphosphate deficiency in liver and hepatoma cells. In: Keppler D (ed) Pathogenesis and mechanisms of liver cell necrosis. MTP Press, Lancaster, pp 87–101
Keppler D (1977) Uridine triphosphate deficiency, growth inhibition, and death in ascites hepatoma cells induced by a combination of pyrimidine biosynthesis inhibition with uridylate trapping. Cancer Res 37: 911–917
Keppler D (1978) Approaches to the chemotherapy of hepatomas. In: Remmer H, Bolt HM, Bannasch P, Popper H (eds) Primary liver tumors. MTP Press, Lancaster, pp 485–492
Keppler D, Holstege A (1982) Pyrimidine nucleotide metabolism and its compartmentation. In: Sies H (ed) Metabolic compartmentation. Academic Press, London, pp 147–203
Keppler D, Pausch J, Decker K (1974) Selective uridine triphosphate deficiency induced by Dgalactosamine in liver and reversed by pyrimidine nucleotide precursors. Effect on ribonucleic acid synthesis. J Biol Chem 249: 211–216
Keppler D, Schulz-Holstege C, Fauler J, Reiffen KA, Schneider F (1982) Uridylate trapping, induction of UTP deficiency, and stimulation of pyrimidine synthesis de novo by D-galactosone. Biochem J 206: 139–146
Keppler D, Fauler J, Gasser T, Holstege A, Leube K, Schulz-Holstege C, Weckbecker G (1985) Uridylate-trapping sugar analogs in combination with inhibitors of uridylate synthesis de novo and 5-fluorouridine. Adv Enzyme Regul 23: 61–79
Reutter W, Bauer C (1978) Terminal sugars in glycoconjugates: Metabolism of free and protein-bound L-fucose, N-acetyl-neuraminic acid and D-galactose in liver and Morris hepatomas. In: Morris HP, Criss WE (eds) Morris hepatoma. Plenum Publ., Amsterdam, New York, pp 405–437
Tatibana M, Shigesada K (1972) Two carbamyl phosphate synthetases of mammals: specific roles in control of pyrimidine and urea biosynthesis. Adv Enzyme Regul 10: 249–271
Weber G (1983) Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. Cancer Res 43: 3466–3492
Weckbecker G, Keppler D (1984) Substrate properties of 5-fluorouridine diphospho sugars detected in hepatoma cells. Biochem Pharmacol 33: 2291–2298
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Keppler, D., Holstege, A. (1986). Biochemical Basis for Improving Chemotherapeutic Regimens in Liver Malignancies. In: Herfarth, C., Schlag, P., Hohenberger, P. (eds) Therapeutic Strategies in Primary and Metastatic Liver Cancer. Recent Results in Cancer Research, vol 100. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82635-1_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-82635-1_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82637-5
Online ISBN: 978-3-642-82635-1
eBook Packages: Springer Book Archive